Sign in
TerminatedPhase 1

Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases

Key facts

Who runs it
Yale University
Where
New Haven, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 1
People taking part
7 people enrolled
Started
21 Feb 2023
Ended
31 Jan 2024
Type of study
Interventional, 2 groups
Treatments tested
  • adnectin 18F-BMS-986192 Head and Neck Cancer
  • adnectin 18F-BMS-986192 Brain Metastases
Record updated
15 February 2024
Why it stopped
PI changed institutions

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • Patients with resectable squamous cell carcinoma of the oropharynx (HPV positive and HPV negative)
  • Resectability will be confirmed by a surgical co-investigator
  • If available, HPV-association determined by institutional p16 testing (CINtec antibody demonstrating strong and diffuse nuclear and cytoplasmic staining is at least 70% of cells)
  • Absolute neutrophil count (ANC) > 1500/microliter, absolute lymphocyte count (ALC) >1000/microliter, hemoglobin > 9 g/dl, platelets > 100,000/microliter
  • aspartate aminotransferase (AST) and alanine transaminase (ALT) < 5 x upper limit of normal. Bilirubin < 1.5 x upper limit of normal
  • Albumin > 0 g/dl
  • Creatinine < 5 x upper limit of normal
  • Women of child-bearing potential must have a negative serum pregnancy test within 7 days prior to treatment
  • Patients with brain metastases
  • Tumor size equal or greater than 1 cm
  • Resectability or need for laser interstitial thermal therapy (LITT) will be confirmed by a surgical co-investigator
  • Absolute neutrophil count (ANC) > 1500/microliter, absolute lymphocyte count (ALC) >1000/microliter, hemoglobin > 9 g/dl, platelets > 100,000/microliter
  • AST and ALT < 5 x upper limit of normal. Bilirubin < 1.5 x upper limit of normal
  • Albumin > 0 g/dl
  • Creatinine < 5 x upper limit of normal
  • Women of child-bearing potential must have a negative serum pregnancy test within 7 days prior to treatment

Who cannot take part

  • Medical contraindication to surgery
  • Concomitant invasive malignancy, or malignancy within 2 years except for hormonally responsive breast or prostate cancer, resected non-melanoma skin cancer, resected uterine cervical carcinoma
  • Prior systemic therapy, radiation or gross resection for the tumor under study
  • Receipt of other systemic therapy including investigational agents, radiation or gross resection for treatment of the tumor under study
  • Medical contraindication to brain surgery
  • Full dose anticoagulation
  • Inability to give informed consent
  • Women may not be pregnant or breast-feeding
  • Full dose anticoagulation
  • Inability to give informed consent
  • Women may not be pregnant or breast-feeding

Where in United States

  • Yale University PET CenterNew Haven, United States

About the trial

What the trial wants to find out

This study aims to determine the feasibility of non-invasive quantitative PD-L1 measurement using [a novel PD-L1 positron emission tomography (PET) tracer and perform immunohistochemistry based measurement of PD-L1 levels within resected lesions in head and neck cancer and brain metastases.

The 2 groups in the trial

  • Head and neck cancerTreatment being tested

    Participants with head and neck squamous cell carcinoma who plan to undergo tumor resection and lymph node resection.

    Treatment: adnectin 18F-BMS-986192 Head and Neck Cancer

  • Brain MetastasesTreatment being tested

    Participants with metastases to the brain from melanoma, lung cancer, breast cancer.

    Treatment: adnectin 18F-BMS-986192 Brain Metastases

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Pilot Study of Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases
Record updated
15 February 2024